

Corresponding author(s):	Cheng-Gang Zou
Last updated by author(s):	Apr 12, 2019

Reporting Summary

X Life sciences

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see <u>Authors & Referees</u> and the <u>Editorial Policy Checklist</u>.

Statistics						
For all statistical analys	es, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.					
n/a Confirmed	a Confirmed					
☐ ☐ The exact sam	ple size (n) for each experimental group/condition, given as a discrete number and unit of measurement					
A statement o	n whether measurements were taken from distinct samples or whether the same sample was measured repeatedly					
The statistical Only common to	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.					
A description	A description of all covariates tested					
A description	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons					
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)					
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>					
For Bayesian a	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings					
For hierarchic	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes					
Estimates of e	Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated					
•	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.					
Software and c	ode					
Policy information about availability of computer code						
Data collection	N/A					
Data analysis	Prism7 GraphPad https://www.graphpad.com ImageJ https://imagej.nih.gov/ij					
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.						
Data						
Policy information about <u>availability of data</u> All manuscripts must include a <u>data availability statement</u> . This statement should provide the following information, where applicable: - Accession codes, unique identifiers, or web links for publicly available datasets - A list of figures that have associated raw data - A description of any restrictions on data availability						
The data that support the findings of this study are available from the corresponding author upon reasonable request.						
Field-specific reporting						

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Ecological, evolutionary & environmental sciences

Behavioural & social sciences

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size Sample size was determined accordingly to previous published study and experimental knowledge.

Data exclusions No data were excluded from the experiments reported.

Replication Experimental findings were highly reproducible each time.

Randomization | Worms were randomly allocated into different experimental groups by pipetting from a single population and into different plates.

Blinding Blinding did not seem necessary.

Timing

Behavioural & social sciences study design

All studies must disclose on these points even when the disclosure is negative.

Study description

Briefly describe the study type including whether data are quantitative, qualitative, or mixed-methods (e.g. qualitative cross-sectional, quantitative experimental, mixed-methods case study).

Research sample State the research sample (e.g. Harvard university undergraduates, villagers in rural India) and provide relevant demographic information

(e.g. age, sex) and indicate whether the sample is representative. Provide a rationale for the study sample chosen. For studies involving existing datasets, please describe the dataset and source.

Sampling strategy

Describe the sampling procedure (e.g. random, snowball, stratified, convenience). Describe the statistical methods that were used to predetermine sample size OR if no sample-size calculation was performed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient. For qualitative data, please indicate whether data saturation was considered, and what criteria were used to decide that no further sampling was needed.

Data collection

Provide details about the data collection procedure, including the instruments or devices used to record the data (e.g. pen and paper, computer, eye tracker, video or audio equipment) whether anyone was present besides the participant(s) and the researcher, and whether the researcher was blind to experimental condition and/or the study hypothesis during data collection.

Indicate the start and stop dates of data collection. If there is a gap between collection periods, state the dates for each sample cohort.

behind them, indicating whether exclusion criteria were pre-established.

Non-participation State how many participants dropped out/declined participation and the reason(s) given OR provide response rate OR state that no participants dropped out/declined participation.

Randomization | If participants were not allocated into experimental groups, state so OR describe how participants were allocated to groups, and if allocation was not random, describe how covariates were controlled.

Ecological, evolutionary & environmental sciences study design

All studies must disclose on these points even when the disclosure is negative.

Study description

Briefly describe the study. For quantitative data include treatment factors and interactions, design structure (e.g. factorial, nested, hierarchical), nature and number of experimental units and replicates.

Research sample

Describe the research sample (e.g. a group of tagged Passer domesticus, all Stenocereus thurberi within Organ Pipe Cactus National Monument), and provide a rationale for the sample choice. When relevant, describe the organism taxa, source, sex, age range and any manipulations. State what population the sample is meant to represent when applicable. For studies involving existing datasets,

describe the data and its source.

Sampling strategy

Note the sampling procedure. Describe the statistical methods that were used to predetermine sample size OR if no sample-size calculation was performed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient.

Timing and spatial scale Indicate the start and stop dates of data collection, noting the frequency and periodicity of sampling and providing a rationale for these choices. If there is a gap between collection periods, state the dates for each sample cohort. Specify the spatial scale from which the data are taken

	If no data were excluded from the analyses, state so OR if data were excluded, describe the exclusions and the rationale behind them, indicating whether exclusion criteria were pre-established.					
	Describe the measures taken to verify the reproducibility of experimental findings. For each experiment, note whether any attempts to repeat the experiment failed OR state that all attempts to repeat the experiment were successful.					
	Describe how samples/organisms/participants were allocated into groups. If allocation was not random, describe how covariates were controlled. If this is not relevant to your study, explain why.					
S	Describe the extent of blinding used during data acquisition and analysis. If blinding was not possible, describe why OR explain why blinding was not relevant to your study.					
Did the study involve field w	work? Yes No					
Field work, collecti	on and transport					
Field conditions	Describe the study conditions for field work, providing relevant parameters (e.g. temperature, rainfall).					
Location	State the location of the sampling or experiment, providing relevant parameters (e.g. latitude and longitude, elevation, water depth).					
Access and import/export	Describe the efforts you have made to access habitats and to collect and import/export your samples in a responsible manner and in compliance with local, national and international laws, noting any permits that were obtained (give the name of the issuing authority, the date of issue, and any identifying information).					
Disturbance	Describe any disturbance caused by the study and how it was minimized.					
Materials & experiment n/a Involved in the study Antibodies Eukaryotic cell lines Palaeontology Animals and other org Human research partic Clinical data	n/a Involved in the study ChIP-seq Flow cytometry MRI-based neuroimaging anisms					
Antibodies						
Antibodies used	GFP (7G9) Mouse mAb (Abmart) cat#M20004: WB Actin (C4) Mouse mAb (Abcam) cat#ab14128: WB					
Validation	GFP Mouse mAb, (Abmart),cat#M20004: Western blot analysis of extracts from worms.(see manufacturer's website). Actin Mouse mAb (Abcam) cat#ab14128: Western blot analysis of extracts from worms. (see manufacturer's website).					
Eukaryotic cell line	S S					
Policy information about <u>cell</u>	<u> </u>					
Cell line source(s)	State the source of each cell line used.					
Authentication	Describe the authentication procedures for each cell line used OR declare that none of the cell lines used were authenticated.					
Mycoplasma contamination	Confirm that all cell lines tested negative for mycoplasma contamination OR describe the results of the testing for mycoplasma contamination OR declare that the cell lines were not tested for mycoplasma contamination.					
Commonly misidentified lin (See ICLAC register)	Traine any commonly moracherized commes accam are stady and provide a rational of their acci					

Specimen provenance

Provide provenance information for specimens and describe permits that were obtained for the work (including the name of the issuing authority, the date of issue, and any identifying information).

Specimen deposition

Indicate where the specimens have been deposited to permit free access by other researchers.

Dating methods

If new dates are provided, describe how they were obtained (e.g. collection, storage, sample pretreatment and measurement), where they were obtained (i.e. lab name), the calibration program and the protocol for quality assurance OR state that no new dates are provided.

Tick this box to confirm that the raw and calibrated dates are available in the paper or in Supplementary Information.

Animals and other organisms

Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research

Laboratory animals The study involved Cs worms, but no vertebrates, nor higher invertebrates.

Wild animals The study did not involve wild animals.

Field-collected samples The study did not involve field-collected samples.

Ethics oversight No ethical approval or guidance was needed.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Human research participants

Policy information about studies involving human research participants

Population characteristics

Describe the covariate-relevant population characteristics of the human research participants (e.g. age, gender, genotypic information, past and current diagnosis and treatment categories). If you filled out the behavioural & social sciences study design questions and have nothing to add here, write "See above."

Recruitment

Describe how participants were recruited. Outline any potential self-selection bias or other biases that may be present and how these are likely to impact results.

Ethics oversight

Identify the organization(s) that approved the study protocol.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Clinical data

Policy information about <u>clinical studies</u>

All manuscripts should comply with the ICMJE guidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions.

Clinical trial registration

Provide the trial registration number from ClinicalTrials.gov or an equivalent agency.

Study protocol

Note where the full trial protocol can be accessed OR if not available, explain why.

Data collection

Describe the settings and locales of data collection, noting the time periods of recruitment and data collection.

Outcomes

Describe how you pre-defined primary and secondary outcome measures and how you assessed these measures.

ChIP-seq

Data deposition

Confirm that both raw and final processed data have been deposited in a public database such as GEO.

Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

Data access links

May remain private before publication.

For "Initial submission" or "Revised version" documents, provide reviewer access links. For your "Final submission" document, provide a link to the deposited data.

Files in database submission

Provide a list of all files available in the database submission.

Genome browser session

(e.g. <u>UCSC</u>)

Provide a link to an anonymized genome browser session for "Initial submission" and "Revised version" documents only, to enable peer review. Write "no longer applicable" for "Final submission" documents.

Methodology

Replicates

Describe the experimental replicates, specifying number, type and replicate agreement.

Sequencing depth

Describe the sequencing depth for each experiment, providing the total number of reads, uniquely mapped reads, length of reads and whether they were paired- or single-end.

Antibodies

Describe the antibodies used for the ChIP-seq experiments; as applicable, provide supplier name, catalog number, clone name, and lot number.

name, and lot number.

Peak calling parameters

Specify the command line program and parameters used for read mapping and peak calling, including the ChIP, control and index files used.

Data quality

Describe the methods used to ensure data quality in full detail, including how many peaks are at FDR 5% and above 5-fold

enrichment.

Software

Describe the software used to collect and analyze the ChIP-seq data. For custom code that has been deposited into a community repository, provide accession details.

Flow Cytometry

Plots

(Confirm that:
	The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
	The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers)
	All plots are contour plots with outliers or pseudocolor plots.
	A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation Describe the sample preparation, detailing the biological source of the cells and any tissue processing steps used.

Instrument Identify the instrument used for data collection, specifying make and model number.

Software Describe the software used to collect and analyze the flow cytometry data. For custom code that has been deposited into a

community repository, provide accession details.

Cell population abundance Describe the abundance of the relevant cell populations within post-sort fractions, providing details on the purity of the samples and how it was determined.

Gating strategy

Describe the gating strategy used for all relevant experiments, specifying the preliminary FSC/SSC gates of the starting cell population, indicating where boundaries between "positive" and "negative" staining cell populations are defined.

Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.

Magnetic resonance imaging

Experimental design

Design type Indicate task or resting state; event-related or block design.

Design specifications

Specify the number of blocks, trials or experimental units per session and/or subject, and specify the length of each trial or block (if trials are blocked) and interval between trials.

at short (i) that are shortes) and meet an section and

Behavioral performance measures

State number and/or type of variables recorded (e.g. correct button press, response time) and what statistics were used to establish that the subjects were performing the task as expected (e.g. mean, range, and/or standard deviation across subjects).

Acquisition				
Imaging type(s) Specify: fund		tional, structural, diffusion, perfusion.		
Field strength	Specify in Tes	sla		
Sequence & imaging parameters		Specify the pulse sequence type (gradient echo, spin echo, etc.), imaging type (EPI, spiral, etc.), field of view, matrix size, slice thickness, orientation and TE/TR/flip angle.		
Area of acquisition	State whether	State whether a whole brain scan was used OR define the area of acquisition, describing how the region was determined.		
Diffusion MRI Used	Not use	d		
Preprocessing				
Preprocessing software		Provide detail on software version and revision number and on specific parameters (model/functions, brain extraction, segmentation, smoothing kernel size, etc.).		
Normalization		data were normalized/standardized, describe the approach(es): specify linear or non-linear and define image types sed for transformation OR indicate that data were not normalized and explain rationale for lack of normalization.		
		template used for normalization/transformation, specifying subject space or group standardized space (e.g. irach, MNI305, ICBM152) OR indicate that the data were not normalized.		
Noise and artifact removal		r procedure(s) for artifact and structured noise removal, specifying motion parameters, tissue signals and signals (heart rate, respiration).		
Volume censoring Define your s		software and/or method and criteria for volume censoring, and state the extent of such censoring.		
Statistical modeling & inference	9			
		(mass univariate, multivariate, RSA, predictive, etc.) and describe essential details of the model at the first evels (e.g. fixed, random or mixed effects; drift or auto-correlation).		
Effect(s) tested	Define precise effect in terms of the task or stimulus conditions instead of psychological concepts and indicate whether ANOVA or factorial designs were used.			
Specify type of analysis: Whole	e brain	ROI-based Both		
Statistic type for inference (See <u>Eklund et al. 2016</u>)	Specify voxel	-wise or cluster-wise and report all relevant parameters for cluster-wise methods.		
Correction Describe the Carlo).		type of correction and how it is obtained for multiple comparisons (e.g. FWE, FDR, permutation or Monte		
Models & analysis				
n/a Involved in the study Functional and/or effective connectivity Graph analysis Multivariate modeling or predictive analysis				
Functional and/or effective connectivity		Report the measures of dependence used and the model details (e.g. Pearson correlation, partial correlation, mutual information).		
Graph analysis		Report the dependent variable and connectivity measure, specifying weighted graph or binarized graph, subject- or group-level, and the global and/or node summaries used (e.g. clustering coefficient, efficiency, etc.).		
Multivariate modeling and predictive analysis		Specify independent variables, features extraction and dimension reduction, model, training and evaluation metrics.		